MDM2/XIAP-IN-1 (compound 14) is an orally active dual inhibitor of MDM2 and XIAP, displaying anti-cancer activity with an IC50 of 0.3 μM and potential applications in cancer research [1].

The chemical compound MDM2/XIAP-IN-1, at a concentration of 0-4 μM administered over a period of 2 weeks, inhibits the cellular activity of EU-1, EU-3, NB-1643, SHEP, and LA1-55n cell lines [1].

MDM2/XIAP-IN-1 Pharmacokinetic Profile in Male SD Rats [1] Pharmacokinetic Analysis [1]: Intravenous administration at a dose of 10 mg/kg resulted in an AUC_last of 4750 ng·h/mL, a half-life (t_1/2) of 0.94 hours, and an observed clearance (Cl_obs) of 2.12 L·h/kg. Oral dosing at 25 mg/kg exhibited an AUC_last of 0.71 ng·h/mL and a bioavailability (F) of 5.9%.